Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

2175 - Metronomic chemotherapy (mCHT) in HER2-ve advanced breast cancer (ABC) patients (pts): old drugs, new opportunities Preliminary results of the VICTOR-6 study

Date

11 Sep 2017

Session

Poster display session

Presenters

Marina Cazzaniga

Citation

Annals of Oncology (2017) 28 (suppl_5): v74-v108. 10.1093/annonc/mdx365

Authors

M. Cazzaniga1, K. Cagossi2, M.R. Valerio3, S. Russo4, V. Casadei5, G. Scognamiglio6, L. Cavanna7, D. Toniolo8, E. De Conciliis9, E. Melegari10, L. Stocchi11, V. Gebbia12, A.M. Vandone13, M.C. Cursano14, G. Pinotti15, R. Rossello16, S. Ortu17, B. Pellegrino18, S. Saracchini19, V. Torri20

Author affiliations

  • 1 Medical Oncology, Osp San Gerardo, 20900 - Monza/IT
  • 2 Medical Oncology, Via Guido Molinari, 2 Carpi (MO) 41012", Modena/IT
  • 3 Medical Oncology, Dipartimento di Oncologia U.O.C di Oncologia Medica Policlinico Universitario di Palermo Via del Vespro, 129, 90127 Palermo, Palermo/IT
  • 4 Medical Oncology, Oncologia PO Vittorio Emanuele, Gela/IT
  • 5 Medical Oncology, ospedali riuniti marche nord, Pesaro/IT
  • 6 Medical Oncology, Ospedale Valduce, 22100 - Como/IT
  • 7 Medical Oncology, Azienda Ospedaliera Piacenza, 29121 - Piacenza/IT
  • 8 Medical Oncology, Azienda Ospedaliera G. Salvini, 20017 - Rho/IT
  • 9 Medical Oncology, ASL Asti, Asti/IT
  • 10 Medical Oncology, IRST Meldola, Meldola/IT
  • 11 Medical Oncology, Ospedale Cervesi, 47841 - Cattolica/IT
  • 12 Medical Oncology, Ospedale La Maddalena, 90100 - Palermo/IT
  • 13 Oncology, A.O. S. Croce e Carle Teaching Hospital, 12100 - Cuneo/IT
  • 14 Medical Oncology, Università Campus Biomedico, Roma/IT
  • 15 Medical Oncology, Ospedale di Circolo Fondazione Macchi, 21050 - Varese/IT
  • 16 Medical Oncology, Osp Taormina, Taormina/IT
  • 17 Medical Oncology, osp Giovanni Paolo II, Olbia/IT
  • 18 Medical Oncology, Azienda Ospedaliera di Parma, 43126 - Parma/IT
  • 19 Medical Oncology, CRO Aviano, Aviano/IT
  • 20 Statistics, Mario Negri, 20133 - Milan/IT
More

Resources

Abstract 2175

Background

mCHT is the minimum biologically effective dose of a chemotherapeutic agent, given at regular dosing regimen with no prolonged drug free interval, that leads to anti-tumor activity. Old regimens included Cyclophosphamide-Methotrexate (CM), whereas in the last years new regimens, such as Vinorelbine (VRL) and Capecitabine (CAPE)-based have been developed. Aim of this observational retrospective ongoing study is to describe the use of mCHT in ABC pts across 5 years and the clinical characteristics of the pts together with efficacy of old (CM-like) vs new (VRL/CAPE-based) metronomic regimens in terms of response and disease control.

Methods

We retrospectively identified from clinical records those HER2-ve ABC pts who have received any kind of mCHT in the years 2011-2015, alone, or in combination with a non-metronomic drug. Standard statistical approaches were used for describing the sample characteristics. Logistic and non proportional hazard analysis were used to identify factors associated with response, and time to treatment failure and survival, respectively. This preliminary analysis focuses on Response Rate (RR) and Disease Control Rate (DCR).

Results

From June 2011 to December 2015, 267 pts have been identified till now and 233 are fully evaluable. Median age at mCHT start was 67 years. 81% was HR+ and 33% had non-visceral metastatic disease. 22% of the pts received CM, 55% VRL-based and 23% mCAPE-based regimens. mCHT use increased over the time from 15.0% (2011) to 30% (2015). As 1st-line treatment, CM was administered in 27% of compared with more than 48% of patients receiving CAPE/VRL-based regimens. Overall Response Rate (ORR) was 28% and Disease Control Rate (DCR) was 79%. Median duration of mCHT was 6.2 months. New generation metronomic regimens produced higher ORR in comparison to old ones (32% vs 13.5%), with similar duration of treatment (6.4 vs 5.4 months, respectively).

Conclusions

The use of mCHT in the treatment of HER2-ve ABC pts has deeply changed across the last 5 years, being new generation regimens used in earlier lines of treatment, producing interesting results in terms of objective response and disease control.

Clinical trial identification

Legal entity responsible for the study

Marina Elena Cazzaniga

Funding

A&Q Consorzio per la riqualificazione agro-alimentare

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.